Interpatient variability in mesothelin expression necessitates its evaluation before gastric cancer immunotherapy.
Immunotherapy
; 14(7): 531-538, 2022 05.
Article
em En
| MEDLINE
| ID: mdl-35321580
ABSTRACT
Aims:
Mesothelin (MSLN) was applied for the immunotherapy of ovarian cancer and mesothelioma with a minimum expression of 60% to obtain a clinical response. Here, the authors evaluated MSLN expression as a potential target of gastric adenocarcinoma immunotherapy. Materials &methods:
The expression of MSLN was evaluated by immunohistochemistry and was reported in primary tumor (PT) and metastatic tumor (MT) sites.Results:
The results showed that only 17.1% and 13.5% of the patients had 60% or more MSLN expression in PT and MT sites, respectively. The expression of MSLN in PTs and MTs was not influenced by Lauren classification, neoadjuvant therapy or tumor stage.Conclusions:
Interpatient variability in MSLN expression necessitates its evaluation before MSLN-based gastric cancer immunotherapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Neoplasias Gástricas
Limite:
Female
/
Humans
Idioma:
En
Revista:
Immunotherapy
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Irã